-
Mashup Score: 3
e19332 Background: US MM-6 is investigating iCT from parenteral V-based induction to all-oral I-lenalidomide-dexamethasone (IRd) with the aim of increasing proteasome inhibitor (PI)-based treatment adherence/duration while maintaining quality of life (QoL) & further improving outcomes in the diverse US community population. Methods: 21 US community sites, including VA hospitals, are enrolling…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
e19332 Background: US MM-6 is investigating iCT from parenteral V-based induction to all-oral I-lenalidomide-dexamethasone (IRd) with the aim of increasing proteasome inhibitor (PI)-based treatment adherence/duration while maintaining quality of life (QoL) & further improving outcomes in the diverse US community population. Methods: 21 US community sites, including VA hospitals, are enrolling…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Long-term proteasome inhibition in US community multiple myeloma Pts following in-class transition (iCT) from parenteral bortezomib to oral ixazomib: Updated real-world data from US MM-6 [May 25, 2020] Girnius et al. #ASCO20 Abst e19332 https://t.co/yu2uHai4Xx #NCT03173092 #mmsm https://t.co/l6rmXJODMP
-
Long-term proteasome inhibition in US community multiple myeloma Pts following in-class transition (iCT) from parenteral bortezomib to oral ixazomib: Updated real-world data from US MM-6 [May 25, 2020] Girnius et al. #ASCO20 Abst e19332 https://t.co/yu2uHai4Xx #NCT03173092 #mmsm